California-based Graph AI, a life sciences startup focusing on patient safety and pharmacovigilance, has secured USD 3 million in seed funding led by Bessemer Venture Partners. The fresh capital will help the company expand its engineering team, enhance product innovation, and accelerate its push into global markets.
Founded in 2024, Graph AI is positioning itself as part of a new wave of AI-native companies reshaping the pharma and life sciences industry. With regulatory authorities mandating continuous drug safety monitoring, the company aims to bring efficiency and intelligence to a traditionally slow and manual process.
Pharma Challenges
Pharmacovigilance is a regulatory requirement that compels pharmaceutical companies to detect, monitor, and report adverse drug events (ADEs) across a drug’s lifecycle—from clinical trials to post-market use. Graph AI is building tools to make this process faster, smarter, and more accurate.
The company’s flagship product, Graph Safety, uses context-aware artificial intelligence and intelligent automation to deliver an end-to-end solution. Already deployed with leading enterprise customers, the platform automates tasks such as case processing, signal detection, aggregate reporting, and regulatory compliance, while creating a centralized intelligence database.
Moving Beyond Manual Work
Traditionally, pharmacovigilance has relied on manual, error-prone, and time-intensive workflows. Graph AI’s platform promises to change this by enabling pharma companies to shift towards highly automated, AI-driven systems. This transition helps reduce human errors, improve compliance, and increase the accuracy of medical reviews.
The broader pharmacovigilance market is valued at USD 8 billion, leaving significant scope for AI-driven disruption. With this funding, Graph AI is preparing to compete aggressively with outdated systems and fragmented point solutions currently used by the industry.
Leadership and Vision
Graph AI is led by Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bordekar (CFO). Together, the founding team brings decades of experience from companies such as Google, Cisco, Infosys, ServiceNow, and LTI Mindtree.
In a joint statement, the founders highlighted the industry’s ongoing struggle with data silos, manual handoffs, and outdated technology. They said Graph AI is solving this with a unified AI-native platform that combines compliance, context, and intelligence in a seamless ecosystem, helping pharma enterprises achieve smarter and safer outcomes.
Investor Confidence
Backing the company, Nithin Kaimal, Partner and COO at Bessemer Venture Partners India, said that Graph AI’s model represents a shift from labour arbitrage to intelligence arbitrage. By focusing on scalability and accuracy, the startup is addressing a crucial gap in global life sciences operations.
Kaimal added that Bessemer is optimistic about the transformative role of AI in traditional service models and looks forward to helping Graph AI scale to new heights in the coming years.
About Graph AI
Graph AI is an AI-first life sciences company that specializes in pharmacovigilance and patient safety. Its core product, Graph Safety, combines automation, compliance, and advanced analytics to modernize drug safety processes. By building a centralized safety intelligence database, the platform enables pharmaceutical and biotech companies to improve efficiency, accuracy, and regulatory trust.
Unlike traditional systems that depend on manual reviews and fragmented tools, Graph AI integrates everything into one intelligent platform. Its mission is to make patient safety smarter, faster, and more connected, ensuring that life-saving drugs are monitored with the highest level of reliability across the world.
